Health Canada Clears Cytokinetics’ MYQORZO for Obstructive HCM
The Canadian authorization covers adults with symptomatic class II-III disease and follows positive results from a Phase 3 trial.
Makkler Newsroom · Oct 19, 02:53 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $109.42 (+94.9%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.